Embecta Corp. (NASDAQ:EMBC) Sees Large Increase in Short Interest

Embecta Corp. (NASDAQ:EMBC) was the target of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 4,703,024 shares, a growth of 16.6% from the February 12th total of 4,034,174 shares. Approximately 8.0% of the company’s shares are short sold. Based on an average daily volume of 773,618 shares, the short-interest ratio is presently 6.1 days. Based on an average daily volume of 773,618 shares, the short-interest ratio is presently 6.1 days. Approximately 8.0% of the company’s shares are short sold.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. BTIG Research reiterated a “buy” rating and issued a $25.00 price objective on shares of Embecta in a research report on Friday, February 6th. Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.50.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $8.93 on Tuesday. The firm has a market capitalization of $528.78 million, a P/E ratio of 3.77 and a beta of 1.10. The stock has a 50 day moving average price of $10.74 and a 200-day moving average price of $12.52. Embecta has a 52-week low of $8.77 and a 52-week high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.04. The company had revenue of $261.20 million for the quarter, compared to analyst estimates of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, equities analysts forecast that Embecta will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date of this dividend is Friday, February 27th. Embecta’s dividend payout ratio (DPR) is 25.32%.

Hedge Funds Weigh In On Embecta

A number of institutional investors and hedge funds have recently made changes to their positions in EMBC. Larson Financial Group LLC boosted its position in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after buying an additional 6,224 shares during the last quarter. Wexford Capital LP bought a new stake in Embecta in the third quarter worth $94,000. Humankind Investments LLC purchased a new stake in shares of Embecta in the second quarter worth $111,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Embecta in the third quarter worth $115,000. Institutional investors own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.